This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

AVEO Pharmaceuticals 관리

관리 기준 확인 2/4

주요 정보

Michael Bailey

최고 경영자

US$2.9m

총 보상

CEO 급여 비율	20.0%
CEO 임기	8yrs
CEO 소유권	1.0%
경영진 평균 재임 기간	2.7yrs
이사회 평균 재임 기간	8yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Michael Bailey 의 보수는 AVEO Pharmaceuticals 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2022	n/a	n/a	-US$29m
Jun 30 2022	n/a	n/a	-US$36m
Mar 31 2022	n/a	n/a	-US$41m
Dec 31 2021	US$3m	US$590k	-US$53m
Sep 30 2021	n/a	n/a	-US$58m
Jun 30 2021	n/a	n/a	-US$56m
Mar 31 2021	n/a	n/a	-US$49m
Dec 31 2020	US$2m	US$565k	-US$36m
Sep 30 2020	n/a	n/a	-US$29m
Jun 30 2020	n/a	n/a	-US$4m
Mar 31 2020	n/a	n/a	US$452k
Dec 31 2019	US$2m	US$528k	US$9m
Sep 30 2019	n/a	n/a	US$36m
Jun 30 2019	n/a	n/a	-US$3m
Mar 31 2019	n/a	n/a	US$4m
Dec 31 2018	US$3m	US$528k	-US$5m
Sep 30 2018	n/a	n/a	-US$24m
Jun 30 2018	n/a	n/a	-US$28m
Mar 31 2018	n/a	n/a	-US$65m
Dec 31 2017	US$1m	US$480k	-US$65m
Sep 30 2017	n/a	n/a	-US$74m
Jun 30 2017	n/a	n/a	-US$53m
Mar 31 2017	n/a	n/a	-US$28m
Dec 31 2016	US$1m	US$444k	-US$27m

보상 대 시장: Michael's total compensation ($USD2.94M) is above average for companies of similar size in the German market ($USD910.42K).

보상과 수익: Michael's compensation has increased whilst the company is unprofitable.

CEO

Michael Bailey (57 yo)

8yrs

테뉴어

US$2,943,905

보상

Mr. Michael P. Bailey serves as an Independent Chairman at IMV Inc. since May 01, 2022 and has been its Independent Director since July 20, 2020. He has been Chief Executive Officer and President of AVEO P...

리더십 팀

이름	위치	테뉴어	보상	소유권
Michael Bailey	CEO, President & Director	8yrs	US$2.94m	0.98% $ 4.7m
Erick Lucera	Chief Financial Officer	3yrs	US$1.24m	0% $ 0
Michael Ferraresso	Chief Commercial Officer	no data	US$1.25m	0.038% $ 184.2k
Jeb Ledell	Chief Operating Officer	1.1yrs	데이터 없음	0% $ 0
Danielle Holland	VP of Legal & Corporate Secretary	2yrs	데이터 없음	데이터 없음
Kevin Peacock	Senior Vice President of Marketing	3.2yrs	데이터 없음	데이터 없음
David Crist	Vice President of Sales	2.3yrs	데이터 없음	데이터 없음
Catherine DeRose	Vice President of Human Resources	2.3yrs	데이터 없음	데이터 없음
Lisa Bruneau	VP of Finance & Treasurer	7yrs	데이터 없음	데이터 없음

2.7yrs

평균 재임 기간

54.5yo

평균 연령

경험이 풍부한 관리: VPA1's management team is considered experienced (2.7 years average tenure).

이사회 구성원

이름	위치	테뉴어	보상	소유권
Michael Bailey	CEO, President & Director	8yrs	US$2.94m	0.98% $ 4.7m
Anthony Evnin	Independent Director	20.8yrs	US$127.61k	0.12% $ 578.0k
Kenneth Bate	Independent Chairman	15.1yrs	US$158.73k	0.0011% $ 5.2k
Raju Kucherlapati	Member of Scientific Advisory Board	no data	US$3.00k	데이터 없음
Charles Sawyers	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
H. Horvitz	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Tyler Jacks	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Lynda Chin	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Lewis Cantley	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Gregory Mayes	Independent Director	3.9yrs	US$120.61k	0% $ 0
Douglas Hanahan	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Scarlett Spring	Independent Director	3.2yrs	US$126.84k	0% $ 0

8.0yrs

평균 재임 기간

63yo

평균 연령

경험이 풍부한 이사회: VPA1's board of directors are considered experienced (8 years average tenure).

This company listing is no longer active

AVEO Pharmaceuticals 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

AVEO Oncology Appoints Martin Birkhofer as Its Chief Medical Officer

Insufficient new directors

AVEO Oncology Announces Appointment of Mike Ferraresso to Chief Commercial Officer

AVEO Pharmaceuticals, Inc. Appoints Corinne Epperly as Member of the Board and to Its Nominating and Governance Committee and Compensation Committee

AVEO Pharmaceuticals, Inc. Announces the Departure of Karuna Rubin, Senior Vice President and General Counsel

AVEO Pharmaceuticals, Inc. Announces Management Changes

Recent updates

LG Chem, Ltd. (KOSE:A051910) completed the acquisition of AVEO Pharmaceuticals, Inc. (NasdaqCM:AVEO) from a group of shareholders.

AVEO Oncology Appoints Martin Birkhofer as Its Chief Medical Officer

Insufficient new directors

Third quarter 2022 earnings released: US$0.094 loss per share (vs US$0.30 loss in 3Q 2021)

Aveo Pharmaceuticals, Inc. Withdraws Earnings Guidance for the Year 2022

AVEO Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 07, 2022

AVEO Pharmaceuticals, Inc. Reaffirms Earnings Guidance for the Full Year 2022

Second quarter 2022 earnings released: US$0.24 loss per share (vs US$0.40 loss in 2Q 2021)

AVEO Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 04, 2022

AVEO Pharmaceuticals, Inc.(NasdaqCM:AVEO) dropped from Russell Microcap Value Index

AVEO Oncology Announces Updated National Comprehensive Cancer Network Clinical Practice Guidelines Elevate Fotivda (Tivozanib) to Category 1 Treatment for Relapsed or Refractory Advanced Renal Cell Carcinoma Patients

First quarter 2022 earnings released: US$0.30 loss per share (vs US$0.81 loss in 1Q 2021)

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

AVEO Pharmaceuticals, Inc. Announces Positive New Long-Term PFS Data from Phase 3 TIVO-3 Study of FOTIVDA® in Third- and Fourth-Line Renal Cell Carcinoma

Aveo Oncology Presents Three Posters for Tivozanib/Immunotherapy Combinations at the 2022 ASCO GI Cancers Symposium

Aveo Oncology Highlights Recent Progress and 2022 Outlook

Third quarter 2021 earnings released: US$0.30 loss per share (vs US$0.33 loss in 3Q 2020)

AVEO Oncology Announces Ficlatuzumab Grants Fast Track Designation by the U.S. FDA

AVEO Pharmaceuticals, Inc.(NasdaqCM:AVEO) dropped from Russell 3000E Value Index

AVEO Oncology Announces Positive Results from Randomized Phase 2 Study of Ficlatuzumab in Combination with Cetuximab in Pan-Refractory, Metastatic HNSCC

CANbridge Life Sciences Ltd. and AVEO Pharmaceuticals, Inc. Terminate Collaboration and License Agreement

AVEO Oncology Announces Collaboration with Bristol Myers Squibb to Evaluate Fotivda® in Combination with Opdivo® in Pivotal Phase 3 Tinivo-2 Trial in Io Relapsed Renal Cell Carcinoma

AVEO Oncology Announces U.S. FDA Approval of FOTIVDA (tivozanib) for the Treatment of Adult Patients with Relapsed or Refractory Advanced Renal Cell Carcinoma

AVEO Oncology Announces Appointment of Mike Ferraresso to Chief Commercial Officer

AVEO Pharmaceuticals, Inc. Appoints Corinne Epperly as Member of the Board and to Its Nominating and Governance Committee and Compensation Committee

AVEO Pharmaceuticals, Inc. Announces the Departure of Karuna Rubin, Senior Vice President and General Counsel

AVEO Oncology Announces Results from Phase 1b Portion of DEDUCTIVE Study of Tivozanib (FOTIVDA®) in Combination with IMFINZI® (Durvalumab) in Previously Untreated Metastatic Hepatocellular Carcinoma

AVEO Pharmaceuticals, Inc. Announces Management Changes

AVEO Oncology and EUSA Pharma Announce Annals of Oncology Publication of Data from Phase 1b/2 TiNivo Study in Renal Cell Carcinoma

AVEO Pharmaceuticals, Inc. announced that it has received $7.499997 million in funding from Johnson & Johnson Innovation - JJDC, Inc.

AVEO Pharmaceuticals, Inc.(NasdaqCM:AVEO) dropped from S&P Global BMI Index

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령